Comparative Pharmacology
Head-to-head clinical analysis: LAMPRENE versus RIFAMPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMPRENE versus RIFAMPIN.
LAMPRENE vs RIFAMPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clofazimine binds preferentially to mycobacterial DNA, inhibiting replication and exerting antimicrobial activity. It also has anti-inflammatory properties by modulating immune responses.
Inhibits DNA-dependent RNA polymerase in bacteria, blocking RNA synthesis.
300 mg orally once daily in combination with other antimycobacterial agents.
Oral or IV: 600 mg once daily (10 mg/kg/day). For tuberculosis: 10 mg/kg (max 600 mg) once daily.
None Documented
None Documented
Terminal elimination half-life ranges from 8 to 70 days (mean approximately 14 days) due to extensive tissue storage and slow release; may be longer with chronic dosing.
Terminal elimination half-life is 3–5 hours initially, decreasing to 2–3 hours after repeated dosing due to autoinduction of hepatic microsomal enzymes. In hepatic impairment, half-life may increase to 5–8 hours.
Primarily fecal (unabsorbed drug and biliary excretion); renal excretion accounts for <1% of the dose as unchanged drug and metabolites.
Biliary excretion of unchanged drug (60–65%) and metabolites (15–20%); renal excretion of unchanged drug (15–20%) and metabolites (5–10%); fecal elimination of unabsorbed drug (≤5%).
Category C
Category A/B
Antimycobacterial
Antimycobacterial